01 August 2023
01 August 2023
Sumitomo blames the placebo and the Covid-19 pandemic on the hindered therapeutic effect of ulotaront.
The Clario’s eClinical technology will be integrated with Sitero’s Mentor platform to streamline the clinical trial process.
The company anticipates reporting trial data in the first half of 2025.
The monoclonal antibody BSI-045B will be investigated as a monotherapy and combination therapy in 80 patients with AD.
Maximum tolerated dose or maximum administered dose will be evaluated sequentially and further used during dose expansion.
Pharma companies were awarded more grants by patents authorities in China, delivering almost five times the grants in the US.
J INTS BIO is hoping to enrol 150 patients in the Phase I/II trial of JIN-A02, with sites in South Korea, the US and Thailand.
The study of RP1 together with INCB99280 is anticipated to commence early next year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
